Jason Eriksen

Dr. Jason Eriksen

University of Houston, Houston, TX 77004, United States

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2006 in Nature
Verified
Journal Article
Closed access
PDF file
MBMatt Baker
Matt Baker
IMIan R. Mackenzie
Ian R. Mackenzie
SPStuart M. Pickering-Brown
Stuart M. Pickering-Brown
JGJennifer Gass
Jennifer Gass
RRRosa Rademakers
Rosa Rademakers
MHMike Hutton
Mike Hutton

8 November 2001 in Nature
Verified
Journal Article
Closed access
PDF file
SWSascha Weggen
Sascha Weggen
Jason EriksenJason Eriksen
Jason Eriksen
PDPritam Das
Pritam Das
SSSarah A. Sagi
Sarah A. Sagi
RWRong Wang
Rong Wang
EKEdward H. Koo
Edward H. Koo

1 July 2005 in Neuron
Verified
Journal Article
Closed access
EMEileen McGowan
Eileen McGowan
FPFiona Pickford
Fiona Pickford
Jungsu KimJungsu Kim
Jungsu Kim
LOLuisa Onstead
Luisa Onstead
Jason EriksenJason Eriksen
Jason Eriksen
TGTodd Golde
Todd Golde

21 August 2008 in Human Molecular Genetics
Verified
Journal Article
Open access
RRRosa Rademakers
Rosa Rademakers
Jason EriksenJason Eriksen
Jason Eriksen
MBMatt Baker
Matt Baker
TRTodd Robinson
Todd Robinson
ZAZeshan Ahmed
Zeshan Ahmed
DDDennis W Dickson
Dennis W Dickson
Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients. Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U. In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50-6.73). We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN. A significant reduction in GRN protein was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical methods, mimicking the effect of heterozygous loss-of-function GRN mutations. In support of these findings, the neuropathology of homozygous rs5848 T-allele carriers frequently resembled the pathological FTLD-U subtype of GRN mutation carriers. We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U. Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegenerative disorders.

1 June 2008 in Nature
Verified
Journal Article
Closed access
PDF file
TKThomas L. Kukar
Thomas L. Kukar
TLThomas B. Ladd
Thomas B. Ladd
MBMaralyssa A. Bann
Maralyssa A. Bann
PFPatrick C. Fraering
Patrick C. Fraering
RNRajeshwar Narlawar
Rajeshwar Narlawar
TGTodd E. Golde
Todd E. Golde

17 April 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TKThomas Kukar
Thomas Kukar
MMMichael Paul Murphy
Michael Paul Murphy
Jason EriksenJason Eriksen
Jason Eriksen
SSSarah A Sagi
Sarah A Sagi
SWSascha Weggen
Sascha Weggen
TGTodd E Golde
Todd E Golde